Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632054 · ClinicalTrials.gov registry record · NA
Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 1,283
- Enrollment target
NCT06632054: Completed NA study, sponsored by NYU Langone Health.
NCT06632054 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 1,283 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06632054, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,283 participants
- Enrollment target
Study Summary
The research team will compare the efficacy of targeted text message reminders against currently used phone call reminders at increasing patient completion of fecal immunochemical test (FIT) for colon cancer screening.
Interventions
- BEHAVIORAL Text Message Reminders
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,283 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2025-07-15 |
| Phase | NA |
What the finished NCT06632054 record still lists
NCT06632054 is an interventional study that assigns participants to a tested intervention. Its 1,283 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Text Message Reminders is the first listed.
NCT06632054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06632054 about?
NCT06632054 is a clinical study titled "Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs". The research team will compare the efficacy of targeted text message reminders against currently used phone call reminders at increasing patient completion of fecal immunochemical test (FIT) for colon cancer screening.
What is the current status of trial NCT06632054?
This trial is currently completed. It is a NA study. The enrollment target is 1,283 participants. The study started on 2025-04-07. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT06632054?
The interventions under investigation include: Text Message Reminders (BEHAVIORAL).
Who is sponsoring clinical trial NCT06632054?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06632054's enrollment target sits among peer trials
1,283 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI